Efficacy, Safety, and Drug Survival During the First Year of Biologic Therapy for Psoriasis in Elderly Versus Younger Patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10497421" target="_blank" >RIV/00179906:_____/25:10497421 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00141101 RIV/00216208:11110/25:10497421 RIV/00216208:11120/25:43928379 RIV/00216208:11130/25:10497421 a 9 dalších

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=y1UBdWuZUb" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=y1UBdWuZUb</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ijd.17814" target="_blank" >10.1111/ijd.17814</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy, Safety, and Drug Survival During the First Year of Biologic Therapy for Psoriasis in Elderly Versus Younger Patients

Popis výsledku v původním jazyce

BACKGROUND: Older people represent an increasing proportion of patients treated with biologics for psoriasis. However, data availability is limited due to the underrepresentation of older patients in clinical trials. MATERIALS AND METHODS: This is a multicentric real-world observational study conducted in dermatology centers in the Czech Republic. It aims to compare the efficacy, safety, and drug survival of biologics in psoriasis patients aged &gt;= 65 years with matched controls aged 18-64 years (1:2 ratio) during the first year of treatment. Data were extracted from the prospective BIOREP registry and patient medical records for adverse events (AEs). RESULTS: A total of 265 elderly patients and 530 matched controls were included. In both groups, a similar proportion of patients achieved a Psoriasis Area and Severity Index (PASI) &lt;= 2 after 14 weeks (67% older vs. 63% younger adults), 26 weeks (71% vs. 76%), and 52 weeks (72% vs. 76%). During the first year of biologic therapy, at least one AE was reported in 108 (41%) older and 214 (40%) younger patients. Serious adverse events (SAEs) were reported in 13 (5%) older and 16 (3%) younger patients. Drug survival during the first year of therapy was lower in older (88%) compared to younger patients (96%), especially in those treated with adalimumab (81% vs. 99%). CONCLUSION: The efficacy of biological treatment was comparable between older and younger patients. Despite older people having more comorbidities, SAEs did not increase in this age group. Nonetheless, the survival rate of older patients was notably lower during the treatment period, especially when adalimumab was administered.

Název v anglickém jazyce

Efficacy, Safety, and Drug Survival During the First Year of Biologic Therapy for Psoriasis in Elderly Versus Younger Patients

Popis výsledku anglicky

BACKGROUND: Older people represent an increasing proportion of patients treated with biologics for psoriasis. However, data availability is limited due to the underrepresentation of older patients in clinical trials. MATERIALS AND METHODS: This is a multicentric real-world observational study conducted in dermatology centers in the Czech Republic. It aims to compare the efficacy, safety, and drug survival of biologics in psoriasis patients aged &gt;= 65 years with matched controls aged 18-64 years (1:2 ratio) during the first year of treatment. Data were extracted from the prospective BIOREP registry and patient medical records for adverse events (AEs). RESULTS: A total of 265 elderly patients and 530 matched controls were included. In both groups, a similar proportion of patients achieved a Psoriasis Area and Severity Index (PASI) &lt;= 2 after 14 weeks (67% older vs. 63% younger adults), 26 weeks (71% vs. 76%), and 52 weeks (72% vs. 76%). During the first year of biologic therapy, at least one AE was reported in 108 (41%) older and 214 (40%) younger patients. Serious adverse events (SAEs) were reported in 13 (5%) older and 16 (3%) younger patients. Drug survival during the first year of therapy was lower in older (88%) compared to younger patients (96%), especially in those treated with adalimumab (81% vs. 99%). CONCLUSION: The efficacy of biological treatment was comparable between older and younger patients. Despite older people having more comorbidities, SAEs did not increase in this age group. Nonetheless, the survival rate of older patients was notably lower during the treatment period, especially when adalimumab was administered.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Dermatology

ISSN

0011-9059

e-ISSN

1365-4632

Svazek periodika

64

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

1401-1408

Kód UT WoS článku

001473374100001

EID výsledku v databázi Scopus

2-s2.0-105003801114